A case of long-standing autoimmune type 1 diabetes with common variable immunodeficiency
- 95 Downloads
Several lines of evidence have suggested that pancreatic β-cell destruction is caused by inflammatory cellular responses mediated by T lymphocytes in individuals with type 1A diabetes. B lymphocytes, which play an important role in the production of autoantibodies to β-cell antigens such as insulin, glutamic acid decarboxylase (GAD) or insulinoma associated antigen 2 (IA-2) in type 1A diabetes, are also known as professional antigen-presenting cells and T-lymphocyte activators. Here, we report a case of long-standing autoimmune type 1 diabetes with common variable immunodeficiency, which is known as a functional deficiency of B lymphocytes. A 51-year-old man was admitted to our hospital because of hyperglycemia. He had suffered from frequent bacterial infections from early childhood. At 16 years old, he was diagnosed with common variable immunodeficiency. At age 27, he experienced sudden-onset diabetic ketosis and was diagnosed with type 1 diabetes. Enzyme-linked immunospot (ELISPOT) assay recently revealed that interferon-γ-producing T lymphocytes but not interleukin 4-producing T lymphocytes, which react with GAD and insulin B1-18, were present at increased levels in his peripheral blood at 51 years old. This case represents the longest reported interval between onset of type 1 diabetes and confirmation of cell-mediated autoimmunity against pancreatic β-cells in a patient with common variable immunodeficiency.
KeywordsIDDM CVID ELISPOT GAD IA-2
This study was supported in part by a Grant-in-Aid for Research on Intractable Diseases from the Japanese Ministry of Health, Labour and Welfare. The authors have no relevant conflict of interest to disclose.
- 1.Eisenbarth GS, Polonsky KS, Buse JB. Type 1 diabetes mellitus. In: Larsen PR et al., editors. Williams textbook of endocrinology. 11th ed. Philadelphia: Saunders; 2008. p. 1391–1416.Google Scholar
- 2.Itoh N, Hanafusa T, Miyazaki A, Miyagawa J, Yamagata K, Yamamoto K, Waguri M, Imagawa A, Tamura S, Inada M, Kawata S, Tarui S, Kono N, Matsuzawa Y. Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest. 1993;92:2313–22.PubMedCrossRefGoogle Scholar
- 4.Nagata M, Kotani R, Moriyama H, Yokono K, Roep BO, Peakman M. Detection of autoreactive T cells in type 1 diabetes using coded autoantigens and an immunoglobulin-free cytokine ELISPOT assay: report from the fourth immunology of diabetes society T cell workshop. Ann N Y Acad Sci. 2004;1037:10–5.PubMedCrossRefGoogle Scholar
- 8.Lopez Cruz MC, Martin Mateos MA, Giner Munoz MT, Plaza Martin AM, Sierra Martinez JI. Common variable immunodeficiency, insulin-dependent diabetes mellitus and celiac disease. Allergol Immunopathol (Madr). 2000;28:323–7.Google Scholar
- 10.International Union of Immunological Societies. Primary immunodeficiency diseases, report of an IUIS scientific committee. Clin Exp Immunol. 1999;118(Suppl 1):1–28.Google Scholar
- 11.Serreze DV, Chapman HD, Varnum DS, Hanson MS, Reifsnyder PC, Richard SD, Fleming SA, Leiter EH, Shultz LD. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new “speed congenic” stock of NOD.Ig mu null mice. J Exp Med. 1996;184:2049–53.PubMedCrossRefGoogle Scholar
- 14.Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS. Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361:2143–52.PubMedCrossRefGoogle Scholar
- 19.Quinti I, Soresina A, Spadaro G, Martino S, Donnanno S, Agostini C, Claudio P, Franco D, Maria Pesce A, Borghese F, Guerra A, Rondelli R, Plebani A, Italian Primary Immunodeficiency Network. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol. 2007;27:308–16Google Scholar